DrugPatentWatch Database Preview

Axitinib - Generic Drug Details

What are the generic sources for axitinib and what is the scope of axitinib patent protection?
Axitinib is the generic ingredient in one branded drug marketed by Pf Prism Cv and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Axitinib has one hundred and nine patent family members in fifty-three countries.

There are four drug master file entries for axitinib. Two suppliers are listed for this compound.

Summary for axitinib

International Patents:	109
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	4
Suppliers / Packagers:	2
Bulk Api Vendors:	83
Clinical Trials:	89
Patent Applications:	160
Drug Prices:	see low prices
DailyMed Link:	axitinib at DailyMed

Pharmacology for axitinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Receptor Tyrosine Kinase Inhibitors

Synonyms for axitinib

(E)-N-Methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide
(E)-N-methyl-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide
319460-85-0
460A850
4ag8
4agc
4CA-0215
790713-39-2
AB0008632
AB01274739_02
AB01274739-01
ABP000115
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-013736;Axitinib
AG-13736
AG013736
AG13736
AJ-45709
AK106979
AKOS015902898
AM20090673
AN-501
AOB87786
Axitinib (AG 013736)
Axitinib (JAN/USAN)
Axitinib (VEGFR inhibitor)
Axitinib [USAN:INN:JAN]
Axitinib, >=98% (HPLC)
Axitinib,AG-013736
Axitinib/AG013736
Axitinib\|319460-85-0\|AG 013736\|AG013736
axitinibum
BC659937
BCP9000345
BCPP000372
BDBM25117
Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)-
BRD-K29905972-001-01-4
C22H18N4OS
C9LVQ0YUXG
CAS-319460-85-0
cc-356
CHEBI:66910
CHEBI:94568
CHEMBL1289926
CJ-10777
CS-0116
D01ZRI
D03218
DB06626
DSSTox_CID_28975
DSSTox_GSID_49049
DSSTox_RID_83240
DTXSID3049049
EX-A337
GTPL5659
HE066076
HE334772
HY-10065
I14-1971
Inlyta
Inlyta (TN)
J-502064
KB-02558
KB-74537
KS-1448
MFCD09837898
MLS006010164
MolPort-006-392-413
N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide
N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-1H-indazol-6-yl]sulfanyl]benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
NCGC00241108-01
NCGC00241108-04
NSC-757441
NSC757441
Q-200662
Q-3279
QCR-109
RL03128
S1005
SC-22491
SCHEMBL172918
SMR002530046
SR-01000941566
SR-01000941566-1
ST51054130
SYN1014
Tox21_113597
Tox21_113597_1
TR-013491
UNII-C9LVQ0YUXG
ZINC3816287

US Patents and Regulatory Information for axitinib

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up		Y		➤ Sign Up
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	➤ Sign Up	➤ Sign Up		Y		➤ Sign Up
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Non-Orange Book US Patents for axitinib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
6,891,044	Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use	➤ Sign Up
7,141,587	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	➤ Sign Up
6,531,491	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	➤ Sign Up
6,884,890	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents for axitinib

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration
Denmark	2134702	➤ Sign Up
Eurasian Patent Organization	004460	➤ Sign Up
Cyprus	1107147	➤ Sign Up
Brazil	PI0012352	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for axitinib

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2013 00010	Denmark	➤ Sign Up	PRODUCT NAME: AXITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/12/777/001-006 20120903
2013003,C1218348	Lithuania	➤ Sign Up	PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
1218348/01	Switzerland	➤ Sign Up	FORMER OWNER: AGOURON PHARMACEUTICALS, INC., US
8	Finland	➤ Sign Up
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description